Objective:
To analyze the growth rates of geographic atrophy (GA) in fellow eyes of patients with bilateral GA and validate their use as a control group in clinical trials.
Key Findings:
- Fellow eyes in patients with bilateral GA grow at similar rates to sham-treated eyes.
- The data supports the validity of using fellow eyes as a control group in clinical trials.
- Growth rates of fellow eyes provide internal validation for projected sham treatment outcomes.
Interpretation:
The findings suggest that fellow eyes can serve as a reliable control in clinical trials, reinforcing the efficacy of pegcetacoplan in reducing GA over time.
Limitations:
- The analysis is based on post hoc data, which may have inherent biases.
- The study does not address long-term outcomes beyond the analyzed trials.
Conclusion:
Intervening earlier with C3 inhibitors like pegcetacoplan may lead to better preservation of retinal function in patients with bilateral GA.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
